/
ILMN
$178.18-$2.92 (-1.61%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$26.7B
151M shares
52-week range
$88.00 – $182.84
95% from low
Sector
LABORATORY ANALYTICAL INSTRUMENTS
Exchange
NASDAQ
CS
Borrow rate
0.28%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-292.48
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.33B | $3.54B | $3.24B | $4.53B | $4.58B | $4.50B | $4.37B | $4.34B |
| Cost of revenue | $1.03B | $1.08B | $1.04B | $1.37B | $1.61B | $1.76B | $1.51B | $1.45B |
| Gross profit | $2.30B | $2.47B | $2.20B | $3.15B | $2.97B | $2.74B | $2.86B | $2.89B |
| Gross margin | 69.0% | 69.6% | 68.0% | 69.7% | 64.8% | 60.9% | 65.4% | 66.7% |
| R&D | $623.0M | $647.0M | $682.0M | $1.19B | $1.32B | $1.35B | $1.17B | $951.0M |
| Operating income | $883.0M | $985.0M | $580.0M | −$123.0M | −$4.18B | −$1.07B | −$833.0M | $864.0M |
| EBITDA | $1.13B | $1.36B | $1.09B | $1.20B | −$3.92B | −$608.0M | −$725.0M | $1.46B |
| Net income | $826.0M | $1.00B | $656.0M | $762.0M | −$4.40B | −$1.16B | −$1.22B | $850.0M |
| Net margin | 24.8% | 28.3% | 20.3% | 16.8% | -96.1% | -25.8% | -28.0% | 19.6% |
| EPS (diluted) | 5.54 | 6.72 | 4.43 | 5.05 | -28.05 | -7.35 | -7.69 | 5.45 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $4.6B | $5.23 | $5.16–$5.27 | 11 |
| 2027 | $4.8B | $5.92 | $5.67–$6.25 | 11 |
| 2028 | $5.2B | $6.81 | $6.50–$7.47 | 6 |
| 2029 | $5.6B | $7.91 | $7.80–$8.04 | 2 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Illumina Inc
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
www.illumina.com- Employees
- 8,650
- IPO / List date
- Jul 28, 2000
- HQ
- SAN DIEGO, CA
Held by traders on TradeandTell
No one on the platform currently holds ILMN.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 972,642 | $119.9M |
| Bridgewater Associatesas of 2026-03-31 | 12,751 | $1.6M |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2008-09-23 | 2-for-1 |
Recent trades on TradeandTell
No one on the platform has traded ILMN yet.
